Listed

Pulmatrix, Inc.

PULMNasdaqCIK 1574235HealthcareFiscal year ends Dec 31

Latest reported revenue, Q4 FY2024$3.0kRevenue, Q4 FY2024, three months to 2024-12-31$3.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K/A filed 2026-06-16, accession 0001493152-26-028902. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Dec 31, 2024, from the 10-K/A filed Jun 16, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS−$0.29Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037594.Report this figure+31.0% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$3.0kOperating margin −65066.7%
Diluted EPS−$0.29, Q2 FY2026
Free cash flow−$1.3m, Q4 FY2024
Pulmatrix, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$k366Revenue, Q3 FY2024, three months to 2024-09-30$366.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-16, accession 0001493152-25-018256.Report this figure3.0Revenue, Q4 FY2024, three months to 2024-12-31$3.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K/A filed 2026-06-16, accession 0001493152-26-028902. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%(726.0%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$2.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-16, accession 0001493152-25-018256.Revenue: $366.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-16, accession 0001493152-25-018256.Report this figure(65066.7%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K/A filed 2026-06-16, accession 0001493152-26-028902. Derived: 12-month figure less the 9-month figure.Revenue: $3.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K/A filed 2026-06-16, accession 0001493152-26-028902. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%(706.8%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-16, accession 0001493152-25-018256.Revenue: $366.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-16, accession 0001493152-25-018256.Report this figure(66200.0%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K/A filed 2026-06-16, accession 0001493152-26-028902. Derived: 12-month figure less the 9-month figure.Revenue: $3.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K/A filed 2026-06-16, accession 0001493152-26-028902. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(0.71)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-16, accession 0001493152-25-018256.Report this figurenot reported (Diluted EPS not reported)(0.50)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001493152-26-023368.Report this figure(0.42)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037594.Report this figure(0.24)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-16, accession 0001493152-25-018256.Report this figurenot reported (Diluted EPS not reported)(0.32)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001493152-26-023368.Report this figure(0.29)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001493152-26-037594.Report this figure
Free cash flow$k(3,059)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-16, accession 0001493152-25-018256. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-16, accession 0001493152-25-018256. Derived: 9-month figure less the 6-month figure.Report this figure(1,261)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K/A filed 2026-06-16, accession 0001493152-26-028902. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K/A filed 2026-06-16, accession 0001493152-26-028902. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$7.8mOperating margin −125.1%
Diluted EPS−$1.41, FY2025
Free cash flow−$11.1m, FY2024
Pulmatrix, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m5.2Revenue, FY2021, twelve months to 2021-12-31$5.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-30, accession 0001493152-23-009609.Report this figure6.1Revenue, FY2022, twelve months to 2022-12-31$6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-28, accession 0001493152-24-011630.Report this figure7.3Revenue, FY2023, twelve months to 2023-12-31$7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-21, accession 0001493152-25-011084.Report this figure7.8Revenue, FY2024, twelve months to 2024-12-31$7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K/A filed 2026-06-16, accession 0001493152-26-028902.Report this figurenot reported (Revenue not reported)
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)
Operating margin%(390.2%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$20.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-30, accession 0001493152-23-009609.Revenue: $5.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-30, accession 0001493152-23-009609.Report this figure(312.1%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$18.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-28, accession 0001493152-24-011630.Revenue: $6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-28, accession 0001493152-24-011630.Report this figure(202.0%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$14.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-21, accession 0001493152-25-011084.Revenue: $7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-21, accession 0001493152-25-011084.Report this figure(125.1%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$9.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K/A filed 2026-06-16, accession 0001493152-26-028902.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K/A filed 2026-06-16, accession 0001493152-26-028902.Report this figurenot reported (Revenue not reported)
Net margin%(390.2%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$20.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-30, accession 0001493152-23-009609.Revenue: $5.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-30, accession 0001493152-23-009609.Report this figure(310.3%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$18.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-28, accession 0001493152-24-011630.Revenue: $6.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-28, accession 0001493152-24-011630.Report this figure(193.5%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$14.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-21, accession 0001493152-25-011084.Revenue: $7.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-21, accession 0001493152-25-011084.Report this figure(122.5%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$9.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K/A filed 2026-06-16, accession 0001493152-26-028902.Revenue: $7.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K/A filed 2026-06-16, accession 0001493152-26-028902.Report this figurenot reported (Revenue not reported)
Diluted EPS$ per share(8.63)Diluted EPS, FY2021, twelve months to 2021-12-31−$8.63 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-K filed 2022-03-29, accession 0001493152-22-007957.Report this figure(5.46)Diluted EPS, FY2022, twelve months to 2022-12-31−$5.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-28, accession 0001493152-24-011630.Report this figure(3.87)Diluted EPS, FY2023, twelve months to 2023-12-31−$3.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-21, accession 0001493152-25-011084.Report this figure(2.62)Diluted EPS, FY2024, twelve months to 2024-12-31−$2.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K/A filed 2026-06-16, accession 0001493152-26-028902.Report this figure(1.41)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K/A filed 2026-06-16, accession 0001493152-26-028902.Report this figure
Free cash flow$m(19.9)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$19.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-30, accession 0001493152-23-009609.Capital expenditure: $144.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-30, accession 0001493152-23-009609.Report this figure(19.4)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$19.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-28, accession 0001493152-24-011630.Capital expenditure: $86.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-28, accession 0001493152-24-011630.Report this figure(16.7)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$16.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-21, accession 0001493152-25-011084.Capital expenditure: $676.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-21, accession 0001493152-25-011084.Report this figure(11.1)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$10.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K/A filed 2026-06-16, accession 0001493152-26-028902.Capital expenditure: $398.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K/A filed 2026-06-16, accession 0001493152-26-028902.Report this figurenot reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

Pulmatrix, Inc., open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2015-06-17Oculus Innovative Sciences, Inc.10% owner Sale922,500$2.75$2.5mForm 4
2015-06-16Oculus Innovative Sciences, Inc.10% owner Sale727,500$2.75$2.0mForm 4
2015-03-23Oculus Innovative Sciences, Inc.10% owner Sale350,000$2.75$962.5kForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Pulmatrix, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
RENAISSANCE TECHNOLOGIES LLC2026-06-30$208.6k122,698Added+13,550
BlackRock, Inc.2026-06-30$93.3k54,899Unchanged
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$56.6k33,299Reduced−11,330
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$54.9k32,294Reduced−1,300
SBI Securities Co., Ltd.2026-06-30$53.2k31,285Added+1,200
Shay Capital LLC2026-06-30$32.1k18,857New+18,857
VANGUARD FIDUCIARY TRUST CO2026-06-30$25.0k14,715Unchanged
STATE STREET CORP2026-06-30$23.7k13,945Unchanged
XTX Topco Ltd2026-06-30$20.4k11,991Reduced−1,678
UBS Group AG2026-06-30$875515Added+492

Recent filings

All 645 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Pulmatrix, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2709:00 ET8-K5.07 Shareholder vote results0001493152-26-048644
2026-08-1308:20 ET10-QQuarterly reportPeriod 2026-06-300001493152-26-037594
2026-08-1308:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001493152-26-037592
2026-06-1616:36 ET10-K/AAnnual report, amendedPeriod 2025-12-310001493152-26-028902
2026-05-1508:20 ET10-QQuarterly reportPeriod 2026-03-310001493152-26-023368
2026-05-1508:20 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001493152-26-023367
2026-04-2216:24 ETSCHEDULE 13DOwnership report, active investor0001104659-26-046851
2026-04-2108:00 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001493152-26-018202
2026-03-2717:16 ET8-K1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.01 Change in control; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-013266
2026-03-0208:00 ET8-K1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-26-008449

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1574235
Tickers
PULM
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
Ruthigen, Inc. (to 2015-06-16)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 07:25 ET. Listed shows no prices and gives no investment advice.